DIRECT BILIRUBIN

Back

CLINICAL SIGNIFICANCE
Bilirubin is the product of normal heme catabolism and is excreted in the bile. Bilirubin is increased in certain diseases as in hepatocellular damage (inflammatory, toxic, neoplasmatic), intra or extrahepatic obstruction of the biliary tree, hemolytic diseases, neonatal physiological jaundice, Crigler-Najjar syndrome, Gilbert disease, Dubin-Johnson syndrome, jaundice from maternal milk syndrome, hypothyroidism, fructose intolerance, familial hyperbilirubinemia.

Direct bilirubin increases in intra or extrahepatic obstruction of the biliary tree, in hepatocellular damage (hepatitis, cirrhosis and cancer in advanced stages), Dubin-Johnson syndrome, Rotor syndrome and due to the administration of drugs that cause cholestasis. Theoretically bilirubin should increase in hemolytic anemias. When there are no complications, increase in bilirubin is expected only for the non conjugated fraction. However, in hemolytic anemias without proven complications, some increase in direct bilirubin may be detected.
CHARACTERISTICS

Form: Liquid, ready-to-use
Shelf life: 12 months @ 2-8 C
On-Board Stability: 30 days
Sample: Non hemolysed, non lipemic morning specimen of serum or plasma with heparin or EDTA
Detection limit: 0.04 mg/dL
Linearity: 0.04–20.00 mg/dL


Packaging
For Use On
MEDILYZER
EX-OLYMPUS
GENERAL PURPOSE
SIEMENS ADVIA
Packaging
6x70 Tests
4x200 & 4x350 Tests
R1 3x100 mL, R2 15 mL & R1 2x125 mL, R2 2x125 mL
Please Request Info